全文获取类型
收费全文 | 16004篇 |
免费 | 1353篇 |
国内免费 | 511篇 |
专业分类
耳鼻咽喉 | 172篇 |
儿科学 | 286篇 |
妇产科学 | 377篇 |
基础医学 | 2115篇 |
口腔科学 | 321篇 |
临床医学 | 1871篇 |
内科学 | 2903篇 |
皮肤病学 | 308篇 |
神经病学 | 1093篇 |
特种医学 | 651篇 |
外国民族医学 | 3篇 |
外科学 | 1933篇 |
综合类 | 1164篇 |
一般理论 | 2篇 |
预防医学 | 1042篇 |
眼科学 | 469篇 |
药学 | 1421篇 |
4篇 | |
中国医学 | 345篇 |
肿瘤学 | 1388篇 |
出版年
2024年 | 30篇 |
2023年 | 169篇 |
2022年 | 414篇 |
2021年 | 600篇 |
2020年 | 321篇 |
2019年 | 433篇 |
2018年 | 427篇 |
2017年 | 385篇 |
2016年 | 391篇 |
2015年 | 544篇 |
2014年 | 644篇 |
2013年 | 699篇 |
2012年 | 1149篇 |
2011年 | 1212篇 |
2010年 | 723篇 |
2009年 | 610篇 |
2008年 | 890篇 |
2007年 | 868篇 |
2006年 | 829篇 |
2005年 | 775篇 |
2004年 | 704篇 |
2003年 | 603篇 |
2002年 | 524篇 |
2001年 | 464篇 |
2000年 | 403篇 |
1999年 | 399篇 |
1998年 | 152篇 |
1997年 | 153篇 |
1996年 | 176篇 |
1995年 | 146篇 |
1994年 | 108篇 |
1993年 | 88篇 |
1992年 | 195篇 |
1991年 | 182篇 |
1990年 | 156篇 |
1989年 | 134篇 |
1988年 | 128篇 |
1987年 | 107篇 |
1986年 | 105篇 |
1985年 | 103篇 |
1984年 | 77篇 |
1983年 | 70篇 |
1982年 | 56篇 |
1981年 | 55篇 |
1980年 | 47篇 |
1979年 | 60篇 |
1978年 | 50篇 |
1977年 | 33篇 |
1975年 | 27篇 |
1974年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 10 毫秒
41.
无创性动态血压(ABPM)能较客观地反映血压水平及其昼夜变化规律,对高血压病的诊断、指导用药、药物疗效的评定以及预后评估等均有较大价值。本文对ABPM的发展及临床应用等问题进行综述。 相似文献
42.
43.
H. W. Chu S. Balzar J. Y. Westcott J. B. Trudeau Y. Sun D. J. Conrad S. E. Wenzel 《Clinical and experimental allergy》2002,32(11):1558-1565
BACKGROUND: Although 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE), a product of 15-lipoxygenase (15-LO), may be involved in mild to moderate asthma, little is known about its potential roles in severe asthma. OBJECTIVES: This study was performed to evaluate 15(S)-HETE levels in bronchoalveolar lavage fluid (BALF) from severe asthmatics with and without airway eosinophils and from the control groups. In addition, 15-LO protein expression was examined in endobronchial biopsy, while its expression and activation were evaluated in BAL cells. RESULTS: While 15(S)-HETE levels in BALF were significantly higher in all severe asthmatics than normal subjects, severe asthmatics with airway eosinophils had the highest levels compared with mild, moderate asthmatics and normal subjects. 15(S)-HETE levels were associated with tissue eosinophil numbers, sub-basement membrane thickness and BALF tissue inhibitor of metalloproteinase-1 levels, and were accompanied by increased 15-LO expression in bronchial epithelium. In addition, activation of 15-LO was suggested by the increased proportion of 15-LO in the cytoplasmic membrane of alveolar macrophages from severe asthmatics. CONCLUSION: The data suggest that severe asthmatics with persistent airway eosinophils manifest high levels of 15(S)-HETE in BALF, which may be associated with airway fibrosis. It is likely that 15-LO expression and activation by airway cells explain the increased 15(S)-HETE levels. 相似文献
44.
45.
C E Chu A Cooke J B Stephenson J L Tolmie B Clarke W L Parry-Jones J M Connor M D Donaldson 《Archives of disease in childhood》1994,71(5):441-442
Thirty one patients with the putative diagnosis of Prader-Willi syndrome were reassessed clinically and by DNA analysis. Eleven patients were judged not to have Prader-Willi syndrome and 20 to have the condition. This was confirmed by DNA analysis in all but one case. The diagnosis of Prader-Willi syndrome, especially in early infancy, should be made with caution unless confirmed by molecular genetic studies. 相似文献
46.
There is a great deal of indirect, nonexperimental evidence that a pattern of earlier-stage disease at diagnosis has a better outcome. Increased early detection activities can change, these stage patterns while various biases and the question of generalizability need to be kept in mind in their interpretation. The indirect evidences of possible benefit from early detection activities includes an increase in the number of cases detected, a pattern of more early- and less advanced-stage cases, an increase in the overall site-specific survival rate, and a decrease in the case fatality rate. Unless these intermediate markers are favorable, it is unlikely that early detection will reduce mortality. In addition, one should also differentiate a reduced incidence or a change in treatment as a cause for reduced mortality. 相似文献
47.
The role of various subfamilies of rat hepatic cytochrome P450 in the oxidation of ethosuximide was evaluated by comparing ethosuximide clearance in control rats and those pretreated with relatively selective P450 inducers and/or inhibitors. Clotrimazole pretreatment increased ethosuximide clearance threefold (p less than 0.005). Dexamethasone increased ethosuximide clearance twofold (p less than 0.001), and the dexamethasone effect was completely abolished by a single dose of triacetyloleandomycin. These results suggest a prominent role for cytochrome P450IIIA in ethosuximide metabolism in the rat. Isoniazid increased ethosuximide clearance twofold (p less than 0.001), and this effect was abolished by a single dose of diallylsulfide, suggesting that ethosuximide is also processed by cytochrome P450IIE1 in rats. Phenobarbital pretreatment increased ethosuximide clearance 2-2.7 fold (p less than 0.001); an effect that was only partially reversed by orphenadrine, an inhibitor of cytochrome P450IIB/IIC enzymes. This suggests a quantitatively less important role for the IIB/IIC subfamilies in processing ethosuximide, since phenobarbital is an inducer of P450 subfamilies IIB, IIC, IIE, and IIIA. Neither the cytochrome P450IA inducer, beta-naphthoflavone, nor the inhibitor, alpha-naphthoflavone altered ethosuximide clearance. Ajmaline, an inhibitor of cytochrome P450IID, had no effect on ethosuximide clearance. Together, these findings suggest that ethosuximide is principally oxidized by cytochrome P450IIIA, and that cytochrome P450IIE may play an important role. Cytochromes P450IIB/C play less prominent roles in ethosuximide oxidation, and neither cytochrome P450IA nor cytochrome P450IID is involved. 相似文献
48.
I Chu D C Villeneuve V E Secours R Otson V E Valli 《Journal of toxicology and environmental health》1991,33(3):317-326
The present study was conducted to determine the dermal toxicity of coal coprocessing products and to assess their potential health hazards. Groups of 10 male and 10 female Sprague-Dawley rats were administered dermally coal coprocessing products (light gas oil, LGO; heavy gas oil I, HGOI; heavy gas oil II, HGOII) at 1 g/kg body weight/d for 14 d. The control and positive control groups received normal saline and a coal liquefaction product (CLP) at the same dose level, respectively. Treatment with either the three fractions of coprocessing products or CLP caused decreased growth rate and food consumption in animals of both sexes. Liver enlargement occurred in groups treated with HGOI, HGOII, and CLP. Decreased serum glucose was observed in animals of both sexes treated with the three fractions and CLP. Treatment with HGOI and CLP caused an elevation of hepatic microsomal ethoxyresorufin deethylase activity in the rat of both sexes. The three fractions and CLP caused mild anemia. Mild treatment-related histological changes were observed in the liver, spleen, thyroid, bone marrow, and kidney. All three fractions of coprocessing products were tested for their mutagenicity in five strains of Salmonella typhimurium: TA98, TA100, TA1535, TA1537, and TA1538. HGOI, after metabolic activation, was found to be mutagenic in the strains of TA98, TA100, and TA1538. In contrast, HGOII was mutagenic in the five strains with or without metabolic activation. These data indicate that HGOI and HGOII are more toxic than LGO, and should be subjected to further studies to determine their long-term effects. 相似文献
49.
本文报告了经手术病理证实的53例甲状腺肿瘤,均作了甲状腺造影和B超检查.通过比较分析,我们认为造影对确定肿瘤的良、恶性以及延伸到胸骨后的异位甲状腺肿瘤有其优越性,是一项有效的检查方法;超声则能准确地判断肿瘤的囊、实性,适合碘过敏患者的检查.两种检查各有特点,配合使用有利于对甲状腺肿瘤的诊断和治疗. 相似文献
50.
Jen Te Hsu Chi Ming Chu Shih Tai Chang Hui Wen Cheng Nye Jan Cheng Wan-Ching Ho Chang Min Chung 《Circulation journal》2006,70(12):1611-1616
BACKGROUND: This study investigated the utility of the alveolar - arterial oxygen pressure difference (AaDO (2)) in predicting the short-term prognosis of acute pulmonary embolism (PE). METHODS AND RESULTS: This study retrospectively enrolled 114 consecutive patients with acute PE, diagnosed by either spiral computed tomography or high probability ventilation - perfusion lung scans. During the first 24 h of admission, all patients had initial artery blood gas collected under room air. Patient exclusion criteria were chronic lung disease, septic emboli, and moderate and low probability lung scans. Patients were assigned to 2 groups based on either 30-day death or a 30-day composite event. Receiver operating characteristic analyses was used to determine the AaDO(2) cut-off value for predicting primary and composite endpoints. Statistical analysis demonstrated significant differences in AaDO(2) between the 30-day composite endpoint group and the 30-day composite event-free survival group (p=0.012). The AaDO(2) had a strong trend between the 30-day death group and the survival group (p=0.062). The best cut-off value for AaDO(2) was 53 mmHg and using this, the positive predictive value for 30-day death was 25% and the negative predictive value was 92%. For the 30-day composite endpoint, the positive predictive value for AaDO(2) was 35%, and the negative predictive value was 84%. In this study, thrombocytopenia was also an indicator of poor prognosis for patients with acute PE. CONCLUSION: The AaDO(2) measurement is a highly useful and simple measurement for predicting short-term prognosis in patients with acute PE. It has high negative predictive value and moderate positive predictive value for 30-day death and 30-day composite event. Aggressive thrombolytic treatment strategies should be considered for patients with an initial poor prognostic parameter (ie, AaDO(2) >or=53 mmHg). 相似文献